GLSI
Greenwich Lifesciences Inc
NASDAQ: GLSI · HEALTHCARE · BIOTECHNOLOGY
$18.31
+5.11% today
Updated 2026-10-28
Market cap
$227.22M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.53
Dividend yield
—
52W range
$8 – $34
Volume
0.1M
Greenwich Lifesciences Inc (GLSI) Insider transactions
Net insider activity
Net buying (3,612,917 shares)
Buy transactions
100
Sell transactions
0
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-13 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,800 | $29.83 | $53694.00 |
| 2026-01-12 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,900 | $27.54 | $79866.00 |
| 2025-12-31 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 4,300 | $21.36 | $91848.00 |
| 2025-12-30 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,900 | $21.73 | $63017.00 |
| 2025-12-18 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 4,100 | $12.62 | $51742.00 |
| 2025-11-25 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 4,600 | $8.37 | $38502.00 |
| 2025-11-13 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 100,000 | — | — |
| 2025-11-07 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 10,600 | $8.43 | $89358.00 |
| 2025-10-31 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,300 | $9.26 | $21298.00 |
| 2025-04-25 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,600 | $9.88 | $35568.00 |
| 2025-04-17 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 5,400 | $8.98 | $48492.00 |
| 2025-04-07 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,600 | $9.10 | $32760.00 |
| 2025-04-04 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 5,500 | $8.73 | $48015.00 |
| 2025-01-10 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,500 | $12.51 | $31275.00 |
| 2025-01-07 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,800 | $13.75 | $24750.00 |
| 2025-01-06 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,100 | $13.31 | $14641.00 |
| 2025-01-03 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,400 | $12.95 | $44030.00 |
| 2025-01-02 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $11.97 | $23940.00 |
| 2024-12-31 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,400 | $11.36 | $27264.00 |
| 2024-12-30 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,200 | $11.12 | $35584.00 |
| 2024-12-24 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 149,818 | — | — |
| 2024-12-24 | ROTHE, ERIC | Director | Buy | 41,349 | — | — |
| 2024-12-24 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,148,723 | — | — |
| 2024-12-24 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 25,008 | — | — |
| 2024-12-24 | MCWILLIAMS, DAVID | Director | Buy | 61,984 | — | — |
| 2024-12-24 | HALLOCK, KENNETH | Director | Buy | 41,349 | — | — |
| 2024-12-24 | DAUGHERTY, FRANK JOSEPH | Director, Chief Medical Officer | Buy | 104,890 | — | — |
| 2024-11-21 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 1,000 | $12.91 | $12910.00 |
| 2024-09-26 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,500 | $14.63 | $21945.00 |
| 2024-08-12 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 800 | $13.85 | $11080.00 |
| 2024-08-06 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $13.81 | $27620.00 |
| 2024-08-05 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 5,500 | $13.18 | $72490.00 |
| 2024-08-02 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 1,000 | $15.15 | $15150.00 |
| 2024-07-23 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,500 | $15.89 | $23835.00 |
| 2024-07-18 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 1,000 | $16.00 | $16000.00 |
| 2024-06-13 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 174,825 | $14.30 | $2.50M |
| 2024-04-01 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,000 | $19.08 | $57240.00 |
| 2024-03-22 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,500 | $19.98 | $49950.00 |
| 2024-03-20 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,500 | $17.68 | $26520.00 |
| 2024-03-05 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 30,500 | $12.49 | $380945.00 |
| 2024-03-05 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,500 | $12.49 | $43715.00 |
| 2024-03-04 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 4,100 | $13.03 | $53423.00 |
| 2024-02-16 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 10,800 | $11.16 | $120528.00 |
| 2024-02-15 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 12,700 | $11.07 | $140589.00 |
| 2023-11-10 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 5,000 | $10.17 | $50837.50 |
| 2023-11-03 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,500 | $9.11 | $31885.00 |
| 2023-10-27 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 500 | $8.57 | $4285.00 |
| 2023-10-26 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,500 | $7.97 | $19925.00 |
| 2023-10-25 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,500 | $7.91 | $19775.00 |
| 2023-10-10 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $9.07 | $9070.00 |
| 2023-10-04 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $8.63 | $17260.00 |
| 2023-09-26 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 600 | $8.71 | $5226.00 |
| 2023-09-19 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 4,000 | $8.95 | $35800.00 |
| 2023-09-11 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $9.48 | $9480.00 |
| 2023-08-22 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $9.97 | $9970.00 |
| 2023-08-04 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $10.55 | $21100.00 |
| 2023-07-21 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $9.20 | $9200.00 |
| 2023-07-13 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $9.49 | $2372.50 |
| 2023-05-17 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $11.69 | $11690.00 |
| 2023-04-28 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $11.22 | $2805.00 |
| 2023-04-19 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 7,000 | $11.10 | $77700.00 |
| 2023-04-18 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $11.12 | $22240.00 |
| 2023-04-11 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 1,000 | $11.87 | $11870.00 |
| 2023-04-11 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 5,000 | $12.42 | $62100.00 |
| 2023-03-15 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $12.71 | $3177.50 |
| 2023-03-10 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $12.12 | $12120.00 |
| 2023-02-24 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $15.40 | $3848.75 |
| 2023-02-17 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 600 | $16.53 | $9918.00 |
| 2023-02-10 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $18.68 | $18680.00 |
| 2023-02-03 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $20.84 | $5210.00 |
| 2023-01-27 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $19.20 | $4800.00 |
| 2023-01-27 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $19.35 | $38700.00 |
| 2023-01-20 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,500 | $17.37 | $26055.00 |
| 2023-01-13 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $16.50 | $4125.00 |
| 2023-01-06 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,500 | $15.18 | $22770.00 |
| 2022-12-29 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 4,000 | $15.19 | $60760.00 |
| 2022-12-16 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $12.94 | $3235.00 |
| 2022-12-16 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $13.01 | $13010.00 |
| 2022-12-09 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $13.11 | $26220.00 |
| 2022-12-02 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 250 | $13.98 | $3495.00 |
| 2022-12-02 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $13.84 | $13840.00 |
| 2022-11-02 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $8.79 | $17580.00 |
| 2022-10-14 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 3,000 | $9.75 | $29250.00 |
| 2022-10-07 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 2,000 | $9.72 | $19440.00 |
| 2022-09-30 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $9.46 | $9460.00 |
| 2022-09-29 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,000 | $9.23 | $9230.00 |
| 2022-06-24 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 22,535 | $9.13 | $205744.55 |
| 2022-06-24 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 6,465 | $9.13 | $59025.45 |
| 2022-06-22 | THOMPSON, JAYE | VP Clinical Reg Affairs | Buy | 149,818 | — | — |
| 2022-06-22 | ROTHE, ERIC | Director | Buy | 41,349 | — | — |
| 2022-06-22 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 1,048,723 | — | — |
| 2022-06-22 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 25,008 | — | — |
| 2022-06-22 | MCWILLIAMS, DAVID | Director | Buy | 61,984 | — | — |
| 2022-06-22 | HALLOCK, KENNETH | Director | Buy | 41,349 | — | — |
| 2022-06-22 | DAUGHERTY, FRANK JOSEPH | Director, Chief Medical Officer | Buy | 104,890 | — | — |
| 2022-06-16 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 8,000 | $7.13 | $57040.00 |
| 2022-06-14 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 12,000 | $7.91 | $94920.00 |
| 2022-06-10 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 12,000 | $8.33 | $99960.00 |
| 2022-06-09 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 4,500 | $10.90 | $49050.00 |
| 2022-06-07 | PATEL, SNEHAL | Director, CEO and CFO, 10% Owner | Buy | 6,000 | $8.55 | $51300.00 |
Frequently asked questions
Are GLSI insiders buying or selling?
Over the transactions on record, GLSI insiders have been net buyers, with about $0.00 in stock sold across 0 sales, against 85 open-market purchases.
Does insider selling at GLSI mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.